NIH State-of-the-Science Statement on
Management of the Clinically Inapparent Adrenal Mass ("Incidentaloma")

NIH Consensus and State-of-the-Science Statements
Volume 19, Number 2
February 4–6, 2002
About the NIH Consensus Development Program

NIH Consensus Development and State-of-the-Science Conferences are convened to evaluate the available scientific evidence on a given biomedical or public health topic, often with the purpose of resolving a particular controversial issue in clinical or public health practice. The resultant NIH Consensus Statements and State-of-the-Science Statements are intended to advance understanding of the issue in question and to be useful to health professionals and the public for informed decision-making.

NIH Consensus Statements and State-of-the-Science Statements are prepared by a nonadvocate, non-Federal panel of experts, based on (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session; (2) questions and statements from conference attendees during open discussion periods that are part of the public session; and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government.

The statement reflects the panel’s assessment of medical knowledge available at the time the statement was written. Thus, it provides a “snapshot in time” of the state of knowledge on the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.

Reference Information

For making bibliographic reference to this statement, it is recommended that the following format be used, with or without source abbreviations, but without authorship attribution:


Publications Ordering Information

NIH Consensus Statements, State-of-the-Science Statements, and Technology Assessment Statements and related materials are available by writing to the NIH Consensus Program Information Center, P.O. Box 2577, Kensington, MD 20891; by calling toll free **1-888-NIH-CONSENSUS** (888-644-2667); or by visiting the NIH Consensus Development Program home page at [http://consensus.nih.gov](http://consensus.nih.gov) on the World Wide Web.

Disclosure Statement

All of the panelists who participated in this conference and contributed to the writing of this state-of-the-science statement were identified as having no financial or scientific conflict of interest, and all signed forms attesting to this fact. Unlike the expert speakers who present scientific data at the conference, the individuals invited to participants on NIH State-of-the-Science panels are reviewed prior to selection to assure that they are not proponents of an advocacy position and are not identified with respect to the conference topic with research that could be used to answer any of the conference questions.

Abstract

Objective

To provide health care providers, patients, and the general public with a responsible assessment of currently available data regarding the management of clinically inapparent adrenal masses (“incidentalomas”).

Participants

A non-Federal, nonadvocate, 12-member panel representing the fields of medicine, surgery, endocrinology, pathology, biostatistics, epidemiology, radiology, oncology, and the public. In addition, experts in these same fields presented data to the panel and to a conference audience of approximately 300.

Evidence

Presentations by experts; a systematic review of the medical literature provided by the Agency for Healthcare Research and Quality; and an extensive bibliography of incidentaloma research papers, prepared by the National Library of Medicine. Scientific evidence was given precedence over clinical anecdotal experience.

Conference Process

Answering predefined questions, the panel drafted a statement based on the scientific evidence presented in open forum and the scientific literature. The draft statement was read in its entirety on the final day of the conference and circulated to the experts and the audience for comment. The panel then met in executive session to consider these comments and released a revised statement at the end of the conference. The statement was made available on the World Wide Web at http://consensus.nih.gov immediately after the conference. This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government.
Conclusions

- The management of clinically inapparent adrenal masses is complicated by limited studies of incidence, prevalence, and natural history, including the psychologic impact on the patient who is informed of the diagnosis. Improvements in the resolution of abdominal imaging techniques combined with increased use of abdominal imaging suggest that the prevalence of clinically inapparent adrenal masses will continue to escalate. The low prevalence of adrenal cortical carcinomas and the relatively low incidence of progression to hyperfunction call into question the advisability of the current practice of intense, long-term clinical followup of this common condition.

- All patients with an incidentaloma should have a 1-mg dexamethasone suppression test and a measurement of plasma-free metanephrines.

- Patients with hypertension should also undergo measurement of serum potassium and plasma aldosterone concentration/plasma renin activity ratio.

- A homogeneous mass with a low attenuation value (less than 10 HU) on CT scan is likely a benign adenoma.

- Surgery should be considered in all patients with functional adrenal cortical tumors that are clinically apparent.

- All patients with biochemical evidence of pheochromocytoma should undergo surgery.

- Data are insufficient to indicate the superiority of a surgical or nonsurgical approach to manage patients with subclinical hyperfunctioning adrenal cortical adenomas.
• Recommendations for surgery based upon tumor size are derived from studies not standardized for inclusion criteria, length of followup, or methods of estimating the risk of carcinoma. Nevertheless, patients with tumors greater than 6 cm usually are treated surgically, while those with tumors less than 4 cm are generally monitored. In patients with tumors between 4 and 6 cm, criteria in addition to size should be considered in making the decision to monitor or proceed to adrenalectomy.

• The literature on adrenal incidentaloma has proliferated in the last several years. Unfortunately, the lack of controlled studies makes formulating diagnostic and treatment strategies difficult. Because of the complexity of the problem, the management of patients with adrenal incidentalomas will be optimized by a multidisciplinary team approach involving physicians with expertise in endocrinology, radiology, surgery, and pathology. The paucity of evidence-based data highlights the need for well-designed prospective studies.

• Either open or laparoscopic adrenalectomy is an acceptable procedure for resection of an adrenal mass. The choice of procedure will depend upon the likelihood of an invasive adrenal cortical carcinoma, technical issues, and the experience of the surgical team.

• In patients with tumors that remain stable on two imaging studies carried out at least 6 months apart and do not exhibit hormonal hypersecretion over 4 years, further followup may not be warranted.
Introduction

The adrenals are triangular glands that sit atop each kidney. They influence or regulate the body’s metabolism, salt and water balance, and response to stress by secreting a variety of hormones. Based on autopsy studies, adrenal masses are among the most common tumors in humans: at autopsy, an adrenal mass is found in at least 3 percent of persons over age 50. Most adrenal masses cause no health problems. A small proportion, however, can lead to a number of serious hormonal diseases; approximately 1 out of every 4,000 adrenal tumors is malignant.

Clinically inapparent adrenal masses are discovered inadvertently in the course of diagnostic testing or treatment for other clinical conditions that are not related to suspicion of adrenal disease and, thus, are commonly known as incidentalomas. The definition of incidentaloma excludes patients undergoing imaging procedures as a part of staging and workup for cancer. Improvements in abdominal imaging techniques and technologies have resulted in the detection of an increasing number of adrenal incidentalomas. Increasing clinical and scientific interest is reflected in a twentyfold increase in publications about this condition over the past three decades.

When detected, clinically inapparent adrenal masses raise challenging questions for physicians and their patients. Diagnostic evaluation is performed to determine whether the lesion is hormonally active or nonfunctioning and whether it is malignant or benign. The results from these tests will influence whether the mass is removed surgically or treated nonsurgically. Because the prevalence of these masses increases with age, appropriate management of adrenal tumors will be a growing challenge in our aging society.

Over the past three decades, new information has become available regarding the epidemiology, biology, screening, treatment, and followup of adrenal tumors. For example, recent refinements in the field of minimally invasive surgery have made laparoscopic adrenalectomy a more frequently
used method for removing adrenal masses. Recent reports suggest that up to 20 percent of patients with adrenal incidentalomas have some form of subclinical hormonal dysfunction and may represent a population at higher risk for metabolic disorders and cardiovascular disease. It is important to determine whether groups of patients with subclinical disease benefit from treatment. The psychological impact on the patient of knowing that he or she harbors an adrenal incidentaloma, an incompletely understood clinical problem, merits investigation.

This two-and-a-half-day state-of-the-science conference on Management of the Clinically Inapparent Adrenal Mass (“Incidentaloma”) was convened on February 4–6, 2002, to explore and assess the current knowledge regarding adrenal incidentalomas, so that health care providers and the general public can make informed decisions about this important public health issue.

After a day-and-a-half of expert presentations and questions and public discussion by members of the panel and the audience of interested attendees on incidental adrenal masses, an independent, non-Federal panel weighed the evidence and drafted a statement that was presented on the third day of the conference. Expert presentations and the panel’s statement addressed the following questions:

What are the causes, prevalence, and natural history of clinically inapparent adrenal masses?

• Based on available scientific evidence, what is the appropriate evaluation of a clinically inapparent adrenal mass?

• What criteria should guide the decision on surgical versus nonsurgical management of these masses?

• If surgery is indicated, what is the appropriate procedure?

• What is the appropriate followup for patients for each management approach?

• What additional research is needed to guide practice?
The panel’s draft statement was posted to the Consensus Program Web Site — http://consensus.nih.gov — on Wednesday, February 6, 2002.

The primary sponsors of this meeting were the National Institute of Child Health and Human Development and the NIH Office of Medical Applications of Research. Cosponsors included the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases.

What are the causes, prevalence, and natural history of clinically inapparent adrenal masses?

Clinically inapparent adrenal masses are detected incidentally with imaging studies conducted for other reasons. They may be clinically important because some are caused by adrenal cortical carcinomas (estimated prevalence of 4–12 per million), which have a high mortality rate. The other clinical concern is hormone overproduction from pheochromocytomas, aldosteronomas, and subclinical hypercortisolism, which may be associated with morbidity if untreated.

Prevalence of Clinically Inapparent Adrenal Masses

In autopsy series, the prevalence of clinically inapparent adrenal masses is about 2.1 percent. Because of increased use of noninvasive high-resolution imaging technology, clinically inapparent adrenal masses are being recognized more often. Estimates range from 0.1 percent for general health screening with ultrasound to 0.42 percent among patients evaluated for nonendocrinologic complaints to 4.3 percent among patients who have a previous diagnosis of cancer.

In addition to the source of data (autopsy versus clinical series) and reasons for imaging (cancer workup, nonendocrinologic complaints, general health screening), the prevalence of clinically inapparent adrenal masses varies with age. The prevalence of clinically inapparent adrenal masses detected at autopsy is less than 1 percent for ages younger than 30 years and increases to 7 percent in those 70 years of age or older. Many of these lesions detected at autopsy are very
small. Among patients with clinically inapparent adrenal masses, more are women. This probably reflects the sex distribution of the population undergoing imaging procedures. There is no evidence of a sex difference in prevalence from autopsy studies or general health exams. There is insufficient information to determine whether the prevalence of clinically inapparent adrenal masses differs by the initial diagnostic test.

**Causes of Clinically Inapparent Adrenal Masses**

Clinically inapparent adrenal masses can be either benign or malignant. These include adenomas, pheochromocytomas, myelolipomas, ganglioneuromas, adrenal cysts, hematomas, adrenal cortical carcinomas, metastases from other cancers, and other rare entities.

The distributions of the pathologic origins of clinically inapparent adrenal masses vary with several clinically important factors, including cancer history and mass size. Among cancer patients, three-fourths of clinically inapparent adrenal masses are metastases. In contrast, in populations with no history of cancer, two-thirds of clinically inapparent adrenal masses are benign tumors. The prevalence of primary adrenal cortical carcinoma is clearly related to the size of the tumor. Adrenal cortical carcinoma accounts for 2 percent of tumors less than or equal to 4 cm, 6 percent of tumors 4.1–6 cm, and 25 percent of tumors greater than 6 cm.

Among unselected patients and those with nonendocrinologic complaints, clinically inapparent adrenal masses are most often nonfunctioning tumors (approximately 70 percent). Among patients being evaluated for nonendocrinologic complaints, approximately 5–10 percent have subclinical hypercortisolism (sometimes called “subclinical Cushing syndrome”). The percentage of patients with subclinical hypercortisolism depends on the testing methods and cortisol levels achieved after dexamethasone suppression.

The distribution of clinically inapparent adrenal mass pathologies derived from surgical series will overestimate the prevalence of adrenal cortical carcinoma, since suspicion of adrenal cortical carcinoma is an indication for surgery.
Moreover, the reported frequency of adrenal cortical carcinomas is derived from highly selected patient populations and does not reflect the prevalence rates seen in population-based studies. The age and sex of the patient do not appear to be helpful in predicting the presence of adrenal cortical carcinoma. Distribution estimates from autopsy studies are not biased by surgical indications but may not reflect the risk of adrenal cortical carcinoma among the subset of people undergoing abdominal imaging studies. A precise estimate of the risk of adrenal cortical carcinoma that could guide clinical decisionmaking may not be possible. Almost all the reported large studies used imaging equipment that would now be considered obsolete. The use of contemporary equipment may increase the prevalence of detected clinically inapparent adrenal masses and may enhance our ability to differentiate adrenal cortical carcinomas from adenomas. In addition, the literature comprises mainly small, retrospective studies with variable definitions of clinically inapparent adrenal masses, which cause variation in the relative proportions of adrenal pathological classifications.

**Natural History of Clinically Inapparent Adrenal Masses**

The observed natural history of clinically inapparent adrenal masses varies, depending on the composition of the study population and the size and pathological classification of the adrenal mass. Patients with or without a previous cancer diagnosis found to have adrenal gland metastases will have a clinical course defined by the stage, grade, and site of the primary tumor. Usually, large clinically inapparent adrenal masses (greater than 6 cm) are treated surgically. Approximately 25 percent of masses greater than 6 cm in diameter are adrenal cortical carcinomas, and these patients have very poor clinical outcomes. The overwhelming majority of studies report less than 50 percent 5-year overall survival for adrenal cortical carcinoma, and several report less than 50 percent 2-year overall survival. Inconclusive evidence suggests that adrenalectomy at stage 1 or 2 may improve the survival rate.
Followup of patients with nonfunctioning adrenal masses suggests that 5–25 percent of masses increase in size by at least 1 cm. The threshold for a clinically significant increase in size is unknown. The risk of malignancy is about 1/1,000. Up to 20 percent of patients develop hormone overproduction. Masses greater than or equal to 3 cm are more likely to develop hyperfunction compared to smaller tumors. The interpretation of these followup studies is affected by variable length of followup and variable followup strategies.

Most studies indicate that the transformation rate of small (less than 3 cm) nonfunctioning nodules to functional tumors is low. This may suggest that only limited followup is necessary to detect the clinically inapparent adrenal masses that become biochemically active. Similarly, the high growth rate (or short doubling time) and extremely low incidence of adrenal cortical carcinomas suggest that a judicious followup strategy is sufficient to reassure concerned patients.

**Based on available scientific evidence, what is the appropriate evaluation of a clinically inapparent adrenal mass?**

The patient with a clinically inapparent adrenal mass revealed by an imaging study requires a complete history and physical examination, a biochemical evaluation for hormone excess, and possible additional radiologic studies. The goal is to determine whether the patient has pheochromocytoma, subtle glucocorticoid excess, primary aldosteronism (Conn syndrome), or virilizing or feminizing tumors.

**Hormonal Evaluation**

Available evidence suggests that an overnight (1-mg) dexamethasone suppression test and determination of fractionated urinary and/or plasma metanephrines should be performed. Exceptions will include patients with imaging characteristics of myelolipoma or an adrenal cyst. In patients with hypertension, serum potassium and a plasma aldosterone concentration-plasma renin activity ratio should be determined to evaluate for primary aldosteronism. A plasma aldosterone
concentration-plasma renin activity ratio greater than 30 and a plasma aldosterone concentration of greater than 0.5 nmol/L (20 ng/dL) are highly suggestive of autonomous aldosterone production.

The sensitivity and specificity of 24-hour urine catecholamines for the diagnosis of pheochromocytoma are high, but this test is less sensitive than the determination of free metanephrines, a test now available in commercial laboratories in the United States. Plasma-free metanephrines (normetanephrine, metanephrine) can be measured with high diagnostic sensitivity (99 percent) and good specificity (~89 percent) and are recommended, on the basis of a multicenter study of biochemical tests for the detection of a pheochromocytoma, as the test of choice for excluding or confirming the diagnosis of pheochromocytoma. The rationale for the 1-mg dexamethasone suppression test is to detect subclinical hypercortisolism. After dexamethasone administration, the vast majority of normal individuals suppress their serum cortisol concentration to less than 139.75 nmol/L (5 µg/dL). Some experts, however, propose further testing of individuals with serum cortisol values between 48.7 nmol/L (1.8 µg/dL) and 138.75 nmol/L (5 µg/dL), in addition to patients with the more traditional cutoff of greater than 139.75 nmol/L (5 µg/dL), to increase the detection of subclinical hypercortisolism. However, when lower cutpoints are used, specificity decreases, which results in more false positive test results. Unfortunately, this subclinical syndrome has not been adequately characterized, and its natural history is unknown. A better term for this condition may be subclinical autonomous glucocorticoid hypersecretion. It is controversial whether this disorder is associated with long-term morbidity and whether treatment to reverse subtle glucocorticoid excess is beneficial.

**Radiologic Evaluation**

The size and appearance of an adrenal mass on computed tomography (CT) or magnetic resonance imaging (MRI) may help distinguish between benign and malignant lesions. The available data suggest that nearly all lesions smaller than
4 cm are benign. A standardized measure of X-ray absorption known as CT attenuation value, conventionally expressed in Hounsfield units (HU), may differentiate between benign and malignant lesions. A homogeneous mass with a smooth border and an attenuation value of less than 10 HU on an unenhanced CT study strongly suggests the diagnosis of a benign adrenal adenoma. The optimal diagnostic evaluation has not been established for adrenal masses between 4–6 cm. If these lesions are hormonally inactive and exhibit a benign imaging appearance as described above, they can be monitored. Lesions greater than 6 cm are more likely to be malignant; therefore, surgery should be considered.

Magnetic resonance imaging is equally effective as CT in distinguishing benign from malignant lesions. A benign adenoma exhibits a signal drop on chemical shift imaging and has an intensity similar to that of the liver on a T2-weighted image. Although chemical shift MRI is commonly performed, it does not provide additional information beyond that which is already available on unenhanced CT. The following tests are not widely available, and there are insufficient data regarding their clinical usefulness: radionuclide scintigraphy using iodocholesterol (NP59) for evaluating adrenocortical lesions, I-131 metaiodobenzyl guanidine (MIBG) for evaluating pheochromocytoma, and positron emission tomography (PET).

**Fine-Needle Aspiration**

Computed tomography-guided fine-needle aspiration may be helpful in the diagnostic evaluation of patients with a history of cancer (particularly lung, breast, and kidney), with no other signs of metastases, and a heterogenous adrenal mass with a high attenuation value (greater than 20 HU). Pheochromocytoma should always be excluded before attempting fine-needle aspiration biopsy of an adrenal mass, in order to avoid the potential for hypertensive crisis. A benign cytologic diagnosis on fine-needle aspiration does not, of course, exclude malignancy because of the high false negative rate of this procedure.

There are few data regarding the utility of fine-needle aspiration in patients without a history of malignancy who have an incidentally found adrenal mass.
What criteria should guide the decision on surgical versus nonsurgical management of these masses?

The major issues to be addressed in formulating a therapeutic plan are whether the lesion is clinically or biochemically active (functional) and whether the lesion is likely to be benign or malignant.

If a patient with a unilateral incidentaloma is found on history or physical examination to have the signs and symptoms suggestive of glucocorticoid, mineralocorticoid, adrenal sex hormone, or catecholamine excess that is confirmed biochemically, adrenalectomy is often considered the treatment of choice. However, medical therapy may be appropriate in several situations. For instance, the use of inhibitors of adrenal cortical steroid hormone biosynthesis may be useful when patients with Cushing syndrome are poor surgical candidates. Similarly, aldosterone antagonists may be used to treat an aldosterone-secreting tumor.

In the absence of clinical symptoms, treatment decisions for those patients with biochemical evidence of adrenal hormone excess are not always straightforward. Patients with “silent” pheochromocytomas are at risk for a hypertensive crisis and should undergo adrenalectomy. Adrenalectomy is an option for an individual with hypertension and aldosterone excess. Patients with subclinical autonomous glucocorticoid hypersecretion present a vexing problem. Data indicate that some patients with subtle glucocorticoid excess may develop metabolic derangements, including insulin resistance, that could be attributable to autonomous cortisol hypersecretion or, rarely, may progress to overt Cushing syndrome. The long-term effects of these derangements on the patient are unknown. Adrenalectomy or careful observation has been suggested as a treatment option. However, while adrenalectomy has been demonstrated to correct the biochemical abnormalities, its effect on long-term outcome and quality of life is unknown.

In patients with nonfunctioning incidentalomas, distinguishing between malignant and benign primary adrenal tumors guides subsequent management. Variables to consider are the size of
the lesion, its imaging characteristics, and its growth rate. Traditionally, the size of the lesion has been considered to be the major determinant of the potential presence of a malignant tumor. More than 60 percent of incidentalomas less than 4 cm are benign adenomas, while less than 2 percent represent primary adrenal carcinomas. In contrast, the risk of adrenal carcinoma increases to 25 percent in lesions that are greater than 6 cm, while benign adrenal adenomas account for less than 15 percent. Therefore, the generally accepted recommendation is to excise lesions that are larger than 6 cm. Lesions that are less than 4 cm and appear to be defined as low risk by imaging criteria are unlikely to have malignant potential and are generally not resected. The need and strategy for routine followup in this group are unclear. For lesions between 4 and 6 cm, either close followup or adrenalectomy is considered a reasonable approach. Adrenalectomy should be strongly considered if the imaging findings, including rapid growth rate, decreased lipid content, and other features described previously, suggest that the lesion is not an adenoma. It is important to recognize that the size criteria discussed above are to some degree arbitrary, and treatment recommendations are based upon data derived from highly selected series of patients. Data from several small series of patients indicate that less than 30 percent of incidentalomas increase in size and less than 20 percent develop biochemical abnormalities when followed for up to 10 years. It is reassuring to note that in studies in which patients were monitored for many years, the risk of the lesion being an adrenal cortical carcinoma was extremely low. The clinical condition and personal concerns of an individual patient should be taken into account when making treatment recommendations. Future efforts should be directed toward defining the true natural history of adrenal incidentalomas as a function of size based upon properly designed prospective clinical studies.

Finally, has no known benefits adrenalectomy for patients who, during their workup for a clinically inapparent adrenal mass, are diagnosed with metastasis from a known or unknown primary neoplasm.
If surgery is needed, what is the appropriate procedure?

Either open or laparoscopic adrenalectomy is an acceptable procedure for the resection of an adrenal mass. There are no prospective, randomized trials comparing open with laparoscopic adrenalectomy. Operative mortality associated with adrenalectomy is less than 2 percent. However, the laparoscopic approach may have advantages over the open approach when performed by a surgical team experienced in advanced laparoscopic techniques. These advantages include decreased postoperative pain, reduced time to return of bowel function, decreased length of hospital stay, and the potential for earlier return to work. At present, relative contraindications to laparoscopic adrenalectomy are a definitive or presumed diagnosis of invasive adrenal cortical carcinoma or circumstances that make a minimally invasive approach technically difficult, such as large tumors. No studies demonstrate a consistent benefit of one laparoscopic approach (transabdominal or retroperitoneal) over another.
What is the appropriate followup for patients for each management approach?

Recommendations for followup are designed to detect interval changes in tumor size or the development of hormone overproduction. Long-term followup studies suggest that the vast majority of adrenal lesions remain stable, whereas 5–25 percent enlarge and 3–4 percent decrease in size. However, the limited and incomplete evidence available precludes making specific recommendations regarding serial imaging and biochemical evaluation. In patients whose lesions have not been excised, a CT study repeated 6–12 months after the initial study is reasonable. For lesions that do not increase in size, there are no data to support continued radiologic evaluation. This observation is based on longitudinal studies of up to 10 years reporting that the risk of developing adrenal cortical carcinoma is extremely low.

Hormone excess may develop in up to 20 percent of patients during followup but is unlikely in a patient with a lesion smaller than 3 cm. Cortisol hypersecretion is the most likely disorder that may ensue and is subclinical in two-thirds of cases. The onset of catecholamine overproduction or hyperaldosteronism during long-term followup is rare. Few data are available that would guide recommendations for periodic hormonal testing. One current approach would be to perform an overnight 1-mg dexamethasone suppression test and urine catecholamines/metabolites at yearly intervals or earlier if clinically indicated. The risk of tumor hyperfunction appears to plateau after 3–4 years; however, these data are based on a small number of patients with variable followup.

Patients with subclinical hypercortisolism should receive perioperative glucocorticoids because they are at risk for hypoadrenalism following the removal of the functioning mass. They should be monitored for subsequent hypothalamic-pituitary-adrenal axis recovery and clinical improvement. Guidelines for followup of other patients who have undergone resection have not been defined.
What additional research is needed to guide practice?

Additional research needed to guide practice should be led by the establishment of an international collaborative study group whose charge would be to develop a database of patients with clinically inapparent adrenal masses. The database would need to have clearly defined entry criteria, variables to be collected, guidelines for followup, and so forth. The purpose would be to provide longitudinal data to help address several important questions. These include:

- What is the natural history of clinically silent adrenal masses?
- Can we identify patients who are at high risk for developing adrenal cortical carcinoma?
- How long should patients be monitored before concluding that they are not at risk for adrenal cortical carcinoma or emergence of endocrine hyperfunction?
- What is the optimal followup strategy for patients with incidentally discovered adrenal masses?

Proposed studies are:

1. A study of perioperative and postoperative outcomes designed to define the risks and benefits of the various surgical procedures

2. Studies of physical and mental health outcomes and quality of life among patients with conservatively managed clinically inapparent adrenal masses

3. A study of the effect of surgical removal of tumors on the evolution of common chronic diseases, such as obesity, diabetes, osteoporosis, hypertension, and psychiatric conditions
4. A prospective study at centers conducting screening whole body scans to learn more about the prevalence and natural history of incidentalomas and the psychosocial effect on the patient.

5. A prospective study to characterize subclinical hypercortisolism, including the evaluation of diagnostic tests, possible associated morbidity, and the benefits of treatment.

6. A study to validate the reproducibility of size measurements in serial imaging exams for ultrasound, CT, and MRI and to determine what constitutes a significant change.

Additionally, markers sensitive and specific for adrenal cortical carcinoma need to be identified.

There is a need to better define the various diagnostic tests that have been advocated for evaluating adrenal masses and their translation to clinical practice. These include:

- Positron emission tomography
- Delayed enhanced computed tomography for distinguishing between benign and malignant adrenal neoplasms
- Adrenal biopsies with immunostaining for tumor markers
- 3-mg dexamethasone suppression test versus the 1-mg overnight dexamethasone suppression test
- Utility of plasma free metanephrines measurements for the diagnosis of an adrenal incidentaloma that is a pheochromocytoma
- Finally, the appropriate specialty and surgical societies should develop minimal criteria that define proficiency in the performance of laparoscopic adrenalectomy.
Conclusions

The management of clinically inapparent adrenal masses is complicated by limited studies of incidence, prevalence, and natural history, including the psychologic impact on the patient who is informed of the diagnosis. Improvements in the resolution of abdominal imaging techniques combined with increased use of abdominal imaging suggest that the prevalence of clinically inapparent adrenal masses will continue to escalate. The low prevalence of adrenal cortical carcinomas and the relatively low incidence of progression to hyperfunction call into question the advisability of the current practice of intense, long-term clinical followup of this common condition. All patients with an incidentaloma should have a 1-mg dexamethasone suppression test and a measurement of plasma-free metanephrines. Patients with hypertension should also undergo measurement of serum potassium and plasma aldosterone concentration/plasma renin activity ratio. A homogeneous mass with a low attenuation value (less than 10 HU) on CT scan is likely a benign adenoma. Surgery should be considered in all patients with functional adrenal cortical tumors that are clinically apparent. All patients with biochemical evidence of pheochromocytoma should undergo surgery. Data are insufficient to indicate the superiority of a surgical or nonsurgical approach to manage patients with subclinical hyperfunctioning adrenal cortical adenomas. Recommendations for surgery based upon tumor size are derived from studies not standardized for inclusion criteria, length of followup, or methods of estimating the risk of carcinoma. Nevertheless, patients with tumors greater than 6 cm usually are treated surgically, while those with tumors less than 4 cm are generally monitored. In patients with tumors between 4 and 6 cm, criteria in addition to size should be considered
in making the decision to monitor or proceed to adrenalectomy. The literature on adrenal incidentaloma has proliferated in the last several years. Unfortunately, the lack of controlled studies makes formulating diagnostic and treatment strategies difficult. Because of the complexity of the problem, the management of patients with adrenal incidentalomas will be optimized by a multidisciplinary team approach involving physicians with expertise in endocrinology, radiology, surgery, and pathology. The paucity of evidence-based data highlights the need for well-designed prospective studies. Either open or laparoscopic adrenalectomy is an acceptable procedure for resection of an adrenal mass. The choice of procedure will depend upon the likelihood of an invasive adrenal cortical carcinoma, technical issues, and the experience of the surgical team. In patients with tumors that remain stable on two imaging studies carried out at least 6 months apart and do not exhibit hormonal hypersecretion over 4 years, further followup may not be warranted.
State-of-the-Science Panel

Melvin M. Grumbach, M.D.
Panel and Conference Chairperson

Edward B. Shaw
Professor of Pediatrics Emeritus
Department of Pediatrics
University of California
San Francisco
San Francisco, California

Beverly M.K. Biller, M.D.
Associate Professor of Medicine, Harvard Medical School
Associate Physician in Medicine, Massachusetts General Hospital
Neuroendocrine Unit
Massachusetts General Hospital
Boston, Massachusetts

Glenn D. Braunstein, M.D.
Professor and Chairman
Department of Medicine
Cedars-Sinai Medical Center
University of California
Los Angeles
School of Medicine
Los Angeles, California

Karen K. Campbell
Cushing’s Support and Research Foundation
Pleasanton, California

J. Aidan Carney, M.D., Ph.D.
Emeritus Professor of Pathology
Emeritus Consultant
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, Minnesota

Paul A. Godley, M.D., Ph.D., M.P.P.
Associate Professor of Medicine,
Adjunct Associate Professor, Biostatistics
Adjunct Associate Professor, Epidemiology
Division of Hematology/Oncology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Emily L. Harris, Ph.D., M.P.H.
Senior Investigator
Kaiser Permanente Center for Health Research
Portland, Oregon

Joseph K.T. Lee, M.D., F.A.C.R.
Professor and Chair of Radiology
Department of Radiology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Yolanda C. Oertel, M.D.
Professor Emerita of Pathology
George Washington University
School of Medicine and Health Sciences
Adjunct Professor of Pathology and Laboratory Medicine
MCP Hahnemann University
School of Medicine
Senior Staff Pathologist
Director, Fine-needle Aspiration Service
Pathology Department
Washington Hospital Center
Washington, DC

Mitchell C. Posner, M.D.
Associate Professor of Surgery
Chief, Surgical Oncology
University of Chicago
Chicago, Illinois
Janet A. Schlechte, M.D.
Professor of Medicine
Department of Internal Medicine
University of Iowa Hospitals and Clinics
Iowa City, Iowa

H. Samuel Wieand, Ph.D.
Director
Biostatistics Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Speakers

Alberto Angeli, M.D.
Full Professor of Internal Medicine
University of Turin
Head
Division of Internal Medicine
Dipartimento di Scienze Cliniche e Biologiche
San Luigi Hospital
Orbassano (TO), Italy

David C. Aron, M.D., M.S.
Associate Chief of Staff/Education
Education Office
Louis Stokes Cleveland VA Medical Center 111-W
Cleveland, Ohio

Ethan M. Balk, M.D., M.P.H.
Assistant Director
New England Medical Center Evidence-Based Practice Center
Tufts University School of Medicine
Boston, Massachusetts

Luisa Barzon, M.D.
Research Associate
Department of Histology, Microbiology and Medical Biotechnologies
University of Padova
Padova, Italy

Stefan R. Bornstein, M.D., Ph.D.
Professor of Medicine
Associate Director
Department of Endocrinology
University of Düsseldorf
Düsseldorf, Germany

Clara S. Heffess, M.D.
Chief
Endocrine Division
Armed Forces Institute of Pathology
Washington, DC

Anna A. Kasperlik-Zaluska, M.D., Ph.D.
Professor of Medicine
Department of Endocrinology
Centre for Postgraduate Medical Education
Warsaw, Poland

Job Kievit, M.D., Ph.D.
Director
Department of Medical Decision Making
Leiden University Medical Center
Leiden, The Netherlands

Melvyn Korobkin, M.D.
Professor of Radiology
Director of Abdominal Imaging
Department of Radiology
University of Michigan Medical School
Ann Arbor, Michigan

Ernest E. Lack, M.D.
Professor of Anatomic Pathology
Department of Pathology
Washington Hospital Center
Washington, DC

Joseph Lau, M.D.
Director
New England Medical Center Evidence-Based Practice Center
Tufts University School of Medicine
Boston, Massachusetts
Franco Mantero, M.D.
Professor of Endocrinology
Department of Endocrinology
University of Padova
Padova, Italy

Sandra Ann Murray, Ph.D.
Professor
Department of Cell Biology and Physiology
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania

Karel Pacak, M.D., Ph.D., D.Sc.
Tenure-Track Investigator
Pediatric and Reproductive Endocrinology Branch
National Institute of Child Health and Human Development
National Institutes of Health
Bethesda, Maryland

Martin Reincke, M.D.
Professor of Medicine
University of Freiburg
Freiburg, Germany

Allan E. Siperstein, M.D.
Head, Section of Endoscopic Surgery
Department of General Surgery
Cleveland Clinic Foundation
Cleveland, Ohio

Robert Udelsman, M.D., M.S.B., M.B.A., F.A.C.S.
Lampman Professor of Surgery and Oncology
Chairman
Department of Surgery
Yale University School of Medicine
New Haven, Connecticut

William F. Young, Jr., M.D.
Consultant
Department of Endocrinology and Metabolism
Mayo Clinic and Foundation
Rochester, Minnesota

Planning Committee

Michael Rothberg, M.D., M.P.H.
Consultant
New England Medical Center
Evidence-Based Practice Center
Tufts University School of Medicine
Boston, Massachusetts

Hironobu Sasano, M.D., Ph.D.
Director, Department of Pathology
Tohoku University Hospital
Professor, Department of Pathology
Tohoku University School of Medicine
Sendai, Japan

Duane Alexander, M.D.
Director
National Institute of Child Health and Human Development
National Institutes of Health
Bethesda, Maryland

Jacqueline S. Besteman, J.D., M.A.
Director, EPC Program
Center for Practice and Technology Assessment
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
Rockville, Maryland

David E. Schteingart, M.D.
Professor
Department of Internal Medicine
University of Michigan Medical School
Ann Arbor, Michigan

Stefan R. Bornstein, M.D., Ph.D.
Professor of Medicine
Associate Director
Department of Endocrinology
University of Düsseldorf
Düsseldorf, Germany
John A. Bowersox  
*Communications Specialist*  
Office of Medical Applications of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

Elsa A. Bray  
*Senior Analyst*  
Office of Medical Applications of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

Antonio Fojo, M.D., Ph.D.  
*Chief, Experimental Therapeutics Section*  
Division of Clinical Sciences  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland

Henrietta D. Hyatt-Knorr, M.A.  
*Acting Director*  
Office of Rare Diseases  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

Melvyn Korobkin, M.D.  
*Professor of Radiology*  
Director of Abdominal Imaging  
Department of Radiology  
University of Michigan Medical School  
Ann Arbor, Michigan

Barnett S. Kramer, M.D., M.P.H.  
*Director*  
Office of Medical Applications of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

Ernest E. Lack, M.D.  
*Professor of Anatomic Pathology*  
Department of Pathology  
Washington Hospital Center  
Washington, DC

D. Lynn Loriaux, M.D., Ph.D.  
*Chairman, Department of Medicine*  
Chief, Division of Endocrinology, Diabetes, and Clinical Nutrition  
Oregon Health Sciences University  
Portland, Oregon

Stephen J. Marx, M.D.  
*Branch Chief*  
Metabolic Diseases Branch  
National Institute of Diabetes and Digestive and Kidney Diseases  
National Institutes of Health  
Bethesda, Maryland

Lynnette K. Nieman, M.D.  
*Senior Investigator*  
Pediatric and Reproductive Endocrinology Branch  
National Institute of Child Health and Human Development  
National Institutes of Health  
Bethesda, Maryland

Karen Patrias, M.L.S.  
*Senior Resource Specialist*  
Public Services Division  
National Library of Medicine  
National Institutes of Health  
Bethesda, Maryland
Conference Sponsors

Cynthia A. Rooney
Program Analyst
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

Susan Rossi, Ph.D., M.P.H.
Deputy Director
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

David E. Schteingart, M.D.
Professor
Department of Internal Medicine
University of Michigan Medical School
Ann Arbor, Michigan

Robert Udelsman, M.D., M.S.B., M.B.A., F.A.C.S.
Lampman Professor of Surgery and Oncology
Chairman
Department of Surgery
Yale University School of Medicine
New Haven, Connecticut

Judith M. Whalen, M.P.A.
Associate Director for Science Policy, Analysis, and Communication
National Institute of Child Health and Human Development
National Institutes of Health
Bethesda, Maryland

National Institute of Child Health and Human Development
Duane Alexander, M.D.
Director

Office of Medical Applications of Research
Barnett S. Kramer, M.D., M.P.H.
Director

Conference Cosponsors

National Cancer Institute
Andrew C. von Eschenbach, M.D.
Director

National Institute of Diabetes and Digestive and Kidney Diseases
Allen M. Spiegel, M.D.
Director